Skip to content
Aerami Therapeutics

Aerami Therapeutics

Reimagining the treatment of chronic diseases with Inhaled Therapies

  • ABOUT US
  • Inhalation Technology
  • Pipeline
  • INVESTORS + MEDIA
  • CONTACT
  • linkedin
  • twitter

In The News

Aerami KOL Call: Inhaled Imatinib (AER-901) for the Treatment of Pulmonary Arterial Hypertension

August 18, 2020
Continue Reading

Nurturing The Next Generation Of Top Talent

June 25, 2020
Continue Reading

Working Life – June 2020

June 25, 2020
Continue Reading

Durham-based startup targeting diabetes raises $4.6M, looks for another $10.4M

June 19, 2020
Continue Reading

Seeking Success Where Others Have Failed

December 20, 2019
Continue Reading

Developing A Smart Inhaler For Optimal Drug Delivery

December 16, 2019
Continue Reading

555: Two Worlds, One Career | Mike Kaseta, CFO, Aerami Therapeutics

December 11, 2019
Continue Reading

10 New Ways MedTech Could Keep Diabetes in Check

November 22, 2019
Continue Reading

‘Smart’ inhaler can make insulin delivery quick and painless

October 21, 2019
Continue Reading

The Promise of More Effective Inhaled Endocrine-Focused Therapeutics

October 8, 2019
Continue Reading

Posts navigation

Older posts

Categories

  • In The News
  • PRESS RELEASES

Archives

  • 2022
  • 2021
  • 2020
  • 2019
  • 2017

Investor Contact:

Steve Thornton
Aerami Therapeutics, Inc.
(919) 589-8862
sthornton@aerami.com

Media Contact:

Chad Whitaker
Aerami Therapeutics, Inc.
(919) 355-5864
cwhitaker@aerami.com

  • linkedin
  • twitter

2520 Meridian Parkway, Suite 400
Durham, North Carolina 27713
info@aerami.com

© 2020 Aerami Therapeutics.
All Rights Reserved.  Privacy Policy